drugset / Trial / NCT06649292
SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
The study evaluated the overall survival (OS) of SHR-A1904 versus investigator-selected treatment in second-line CLDN18.2-positive advanced GC/GEJC patients
Timeline
- Start
- 2024-11-22
- Primary completion
- 2027-09-20
- Completion
- 2028-03-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Docetaxel | Small molecule | — | — |
| Comparator | Irinotecan | Small molecule | — | — |
| Comparator | Paclitaxel | Small molecule | — | — |
| Subject | SHR-A1904 | Unknown | — | — |